2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2486

Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)
Abstract Number: 2461

Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Abstract Number: 852

RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody
Abstract Number: 941

Ro/SSA Autoantibody Exposed Neonates Have an Expansion of NK Cells and a Discernible Type II IFN Signature with High IFNγ in Peripheral Blood
Abstract Number: 2579

Rock-Mediated Pkca Nuclear Translocation Is Important in Neutrophil Netosis and UVB Induced-Skin Inflammation
Abstract Number: 1585

Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis
Abstract Number: 649

Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Abstract Number: 901

Role of Epstein Barr Virus Serologic Reactivation in Transitioning to Systemic Lupus Erythematosus in at Risk Individuals
Abstract Number: 1339

Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis
Abstract Number: 651

Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment
Abstract Number: 1642

Role of Plaque in Predicting Cardiovascular Events in Women with Lupus over a 20 Year Followup
Abstract Number: 962

Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 942

Role of the Pyrin Inflammasome in Resistance to Yersinia Pestis: A Possible Selective Advantage for Carriers of MEFV Mutations
Abstract Number: 752

Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
Abstract Number: 1582

RORγt Inhibition Selectively Targets Pathogenic Subsets of Human iNKT and γδ-T Cells Enriched in Spondyloarthritis While Preserving Tissue Protective IL-22 Responses

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].